The global hemostats market size was estimated at USD 2.70 billion in 2023 and is projected to reach USD 4.24 billion by 2030, growing at a CAGR of 6.76% from 2024 to 2030. This growth trajectory is primarily driven by the increasing prevalence of chronic diseases and a rising number of surgical procedures worldwide. As surgical interventions become more complex and widespread, the demand for effective hemostatic agents to manage bleeding during operations has intensified significantly.

Several leading companies in the market are actively pursuing product innovation and regulatory approvals, which is further accelerating market development. A notable example includes Axio Biosolutions, which in March 2023 secured U.S. FDA clearance via the 510(k) pathway for its Ax-Surgi Surgical Hemostat. This novel product is formulated using chitosan, a biopolymer known for its blood-clotting properties, and is specifically designed to control severe surgical bleeding effectively and safely.

Supporting the need for such products, data from the National Center for Biotechnology Information (NCBI) indicates that approximately 60–70% of all transfused red blood cells are administered during surgical procedures. This statistic highlights the critical importance of hemostats in managing postoperative and intraoperative bleeding, which is essential for patient safety and surgical success.

Furthermore, the rising incidence of chronic health conditions such as arthritis and osteoporosis is serving as a significant catalyst for market growth. These conditions often necessitate surgical treatment to relieve pain and restore mobility, such as in joint replacement surgeries.

Key Market Trends & Insights:

• From a regional standpoint, North America emerged as the leading revenue-generating market for hemostats in 2023. This dominance can be attributed to well-established healthcare infrastructure, high volume of surgical procedures, greater adoption of advanced medical technologies, and a strong presence of key market players. Favorable reimbursement policies and ongoing innovations in surgical care further contribute to the region's prominent market position.

• On a country level, the United States is anticipated to record a notable compound annual growth rate (CAGR) during the forecast period from 2024 to 2030. This projected growth is driven by increasing healthcare expenditure, a rising number of surgical interventions—particularly among aging populations—and the rapid introduction of next-generation hemostatic solutions.

• By type, the oxidized regenerated cellulose (ORC)-based hemostats segment held the largest market share, accounting for 44.03% in 2023. The widespread use of ORC-based products is due to their biocompatibility, ease of use, and effectiveness in achieving rapid hemostasis across a range of surgical procedures. These products are particularly favored in both open and minimally invasive surgeries for their ability to control bleeding without inducing tissue damage.

• In terms of formulation, the matrix & gel hemostats segment secured the largest revenue share, representing 38.22% in 2023. These formulations are preferred for their superior adaptability to irregular wound surfaces and ability to conform to complex surgical sites. Their fast action, ease of application, and compatibility with various types of tissues make them particularly effective in managing bleeding during intricate procedures.

Order a free sample PDF of the Hemostats Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 2.70 Billion

• 2030 Projected Market Size: USD 4.24 Billion

• CAGR (2024-2030): 6.76%

• North America: Largest market in 2023

Key Companies & Market Share Insights:

The competitive landscape of the hemostats market is characterized by intense competition, with several leading companies striving to maintain and expand their market positions. Among the most prominent players are Stryker Corporation, B. Braun Melsungen AG, and Baxter International Inc., all of which hold significant shares of the global market. These companies are recognized for their extensive product portfolios, strong distribution networks, and ongoing investments in research and development.

The primary factor fueling this competitive environment is the growing global volume of surgical procedures, which directly drives demand for effective hemostatic solutions. In particular, the increased frequency of orthopedic surgeries—such as joint replacements and fracture repairs—has heightened the need for reliable bleeding control methods. Hemostats play a crucial role in ensuring surgical precision, minimizing blood loss, and promoting better postoperative outcomes, making them indispensable in operating rooms.

To stay competitive, market players are focused on product innovation, securing regulatory approvals, expanding into emerging markets, and forming strategic partnerships. The fast-paced advancements in hemostatic technologies and the need to cater to diverse surgical specialties continue to shape the dynamics of competition within the industry.

Key Players

• Johnson & Johnson

• CryoLife, Inc (Artivion)

• Integra LifeSciences Corporation

• Pfizer

• B. Braun Melsungen AG

• Becton, Dickinson, and Company

• Medtronic

• Baxter

• Stryker Corporation

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global hemostats market is poised for robust growth, driven by a rise in chronic health conditions and an increasing volume of surgeries worldwide. Innovation and new product approvals from major players are accelerating market evolution, while North America remains the lead region. Key product segments—especially cellulose-based and matrix/gel formulations—continue to dominate due to their proven effectiveness and ease of use. Overall, ongoing technological advancements, aging populations, and rising surgical demand suggest sustained expansion and deeper clinical integration.